We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Daily Short Message System (SMS) Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia (SMS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00873249
First Posted: April 1, 2009
Last Update Posted: March 24, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AstraZeneca
  Purpose
This study is a 6-month, multicenter, randomized study to assess the effect of daily SMS reminders sent during 3 months in the adherence to oral antipsychotic treatment in stabilized outpatients with schizophrenia.

Condition
Schizophrenia

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Effect of Daily SMS Reminders on Medication Adherence to Oral Antipsychotics in Patients With Schizophrenia

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Morisky Green Questionnaire [ Time Frame: baseline, at months 3 and 6 ]

Secondary Outcome Measures:
  • Clinical Global Impression- Schizophrenia (CGI-SCH) [ Time Frame: baseline, at months 3 and 6 ]
  • Register of Adherence to Treatment (RAT) [ Time Frame: baseline, at months 3 and 6 ]

Enrollment: 339
Study Start Date: April 2009
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Stabilized outpatients with a diagnosis of schizophrenia
Criteria

Inclusion Criteria:

  • Male or female patients older than 18 years
  • With a diagnosis of schizophrenia (DSM-IV TR criteria)
  • Stabilized out-patients
  • Under oral antipsychotic monotherapy

Exclusion Criteria:

  • Administration of a depot antipsychotic drug
  • Suicide risk
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00873249


Locations
Spain
Research Site
Berga, Barcelona, Spain
Research Site
Sabadell, Barcelona, Spain
Research Site
Santander, Cantabria, Spain
Research Site
Pamplona, Navarra, Spain
Research Site
Calatayud, Zaragoza, Spain
Research Site
Alicante, Spain
Research Site
Almeria, Spain
Research Site
Barcelona, Spain
Research Site
Burgos, Spain
Research Site
Cordoba, Spain
Research Site
Granada, Spain
Research Site
Leon, Spain
Research Site
Lerida, Spain
Research Site
Madrid, Spain
Research Site
Malaga, Spain
Research Site
Murcia, Spain
Research Site
Oviedo, Spain
Research Site
Palma Mallorca, Spain
Research Site
Salamanca, Spain
Research Site
Sevilla, Spain
Research Site
Tarragona, Spain
Research Site
Toledo, Spain
Research Site
Valencia, Spain
Research Site
Valladolid, Spain
Research Site
Zamora, Spain
Sponsors and Collaborators
AstraZeneca
  More Information

Responsible Party: Teresa Diez, AstraZeneca Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00873249     History of Changes
Other Study ID Numbers: NIS-NES-DUM-2007/3
First Submitted: March 31, 2009
First Posted: April 1, 2009
Last Update Posted: March 24, 2010
Last Verified: March 2010

Keywords provided by AstraZeneca:
Schizophrenia
Therapeutic adherence
Short message system
Mobile phone

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs